Zealand Pharma Articles
US FDA accepts Sanofi's NDA for diabetes drug lixisenatide
19 February 2013
Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"
23 November 2012
$20 million lixisenatide milestone for Zealand Pharma
13 February 2012
Sanofi files for EU approval of Lyxumia, a type-2 diabetes agent partnered with Zealand Pharma
4 November 2011
Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting
13 September 2011
Boehringer gains global rights to Zealand’s diabetes/obesity compounds in 376 million-euro deal
17 June 2011
Zealand Pharma gets milestone from Helsinn on ZP1846 progress
10 December 2010
Positive new data on diabetes drugs from Novo Nordisk, AstraZeneca/B-MS and Sanofi-Aventis presented at EASD meeting
21 September 2010
Showing 1-13 of 13 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
